Seoul, South Korea

Hyon Chol Jang

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hyon Chol Jang: Innovator in Cancer Treatment

Introduction

Hyon Chol Jang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative pharmaceutical compositions. With a total of 2 patents, Jang's work focuses on enhancing the efficacy of anticancer agents.

Latest Patents

Hyon Chol Jang's latest patents include a pharmaceutical composition for preventing or treating cancer, which comprises gossypol, phenformin, and various anticancer agents. This invention highlights the synergistic effect achieved when these agents are co-administered, significantly improving the suppression of cancer cell proliferation compared to mono-drug and dual-drug treatments. Another notable patent involves a pharmaceutical composition for cancer treatment that contains gossypol and phenformin as active ingredients. This combination has been verified to exhibit significantly higher anticancer activity than treatments using gossypol or phenformin alone.

Career Highlights

Hyon Chol Jang is affiliated with the National Cancer Center, where he conducts research aimed at developing effective cancer therapies. His work is characterized by a commitment to improving patient outcomes through innovative treatment options.

Collaborations

Jang collaborates with esteemed colleagues, including Soo Youl Kim and Ho Joong Lee, to advance research in cancer treatment. Their combined expertise contributes to the development of groundbreaking pharmaceutical compositions.

Conclusion

Hyon Chol Jang's contributions to cancer treatment through his innovative patents demonstrate his dedication to improving therapeutic strategies. His work continues to pave the way for more effective cancer therapies, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…